Wikidata entity: Q408471
C₁₉H₂₀FNO₃ (P274)
Quantities
| P4250 | defined daily dose | 20 |
| P2067 | mass | 329.143 |
| P3780 | active ingredient in | ... | Q47521971 (Paxil) | Paxil |
| P3780 | active ingredient in | ... | Q47521984 (Pexeva) | Pexeva |
| P3780 | active ingredient in | ... | Q48829260 (Brisdelle) | Brisdelle |
| P233 | canonical SMILES | String | C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4 | ??? |
| P373 | Commons category | String | Paroxetine | ??? |
| P973 | described at URL | Url | Latest News Archive - Community Pharmacy England | ??? |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P527 | has part(s) | ... | Q627 (nitrogen) | nitrogen |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4 | ??? |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P2175 | medical condition treated | ... | Q154430 (anxiety) | anxiety |
| P2175 | medical condition treated | ... | Q178190 (obsessive-compulsive disorder) | obsessive-compulsive disorder |
| P2175 | medical condition treated | ... | Q202387 (post-traumatic stress disorder) | post-traumatic stress disorder |
| P2175 | medical condition treated | ... | Q373822 (eating disorder) | eating disorder |
| P2175 | medical condition treated | ... | Q281928 (social anxiety disorder) | social anxiety disorder |
| P2175 | medical condition treated | ... | Q741713 (panic disorder) | panic disorder |
| P2175 | medical condition treated | ... | Q544006 (anxiety disorder) | anxiety disorder |
| P2175 | medical condition treated | ... | Q845224 (generalized anxiety disorder) | generalized anxiety disorder |
| P2175 | medical condition treated | ... | Q19000444 (neurotic disorder) | neurotic disorder |
| P129 | physically interacts with | ... | Q410142 (solute carrier family 6 member 4) | solute carrier family 6 member 4 |
| P3489 | pregnancy category | ... | Q3679274 (Australian pregnancy category D) | Australian pregnancy category D |
| P3489 | pregnancy category | ... | Q28123618 (US pregnancy category D) | US pregnancy category D |
| P636 | route of administration | ... | Q285166 (oral administration) | oral administration |
| P769 | significant drug interaction | ... | Q18216 (aspirin) | aspirin |
| P769 | significant drug interaction | ... | Q58396 (imipramine) | imipramine |
| P769 | significant drug interaction | ... | Q58397 (amitriptyline) | amitriptyline |
| P769 | significant drug interaction | ... | Q58713 (clomipramine) | clomipramine |
| P769 | significant drug interaction | ... | Q45050 (tenoxicam) | tenoxicam |
| P769 | significant drug interaction | ... | Q55434 (pethidine) | pethidine |
| P769 | significant drug interaction | ... | Q186969 (ibuprofen) | ibuprofen |
| P769 | significant drug interaction | ... | Q181003 (tryptophan) | tryptophan |
| P769 | significant drug interaction | ... | Q218842 (zolpidem) | zolpidem |
| P769 | significant drug interaction | ... | Q304088 (acenocoumarol) | acenocoumarol |
| P769 | significant drug interaction | ... | Q307088 (abciximab) | abciximab |
| P769 | significant drug interaction | ... | Q347941 (parecoxib) | parecoxib |
| P769 | significant drug interaction | ... | Q409192 ((RS)-ketoprofen) | (RS)-ketoprofen |
| P769 | significant drug interaction | ... | Q409231 (indomethacin) | indomethacin |
| P769 | significant drug interaction | ... | Q402633 ((±)-deprenyl) | (±)-deprenyl |
| P769 | significant drug interaction | ... | Q407617 (sertraline) | sertraline |
| P769 | significant drug interaction | ... | Q241006 (desmopressin) | desmopressin |
| P769 | significant drug interaction | ... | Q244408 (Diclofenac) | Diclofenac |
| P769 | significant drug interaction | ... | Q408676 (piroxicam) | piroxicam |
| P769 | significant drug interaction | ... | Q408801 (celecoxib) | celecoxib |
| P769 | significant drug interaction | ... | Q409236 (fluvoxamine) | fluvoxamine |
| P769 | significant drug interaction | ... | Q409595 (isocarboxazid) | isocarboxazid |
| P769 | significant drug interaction | ... | Q416232 (prasugrel) | prasugrel |
| P769 | significant drug interaction | ... | Q418656 (procarbazine) | procarbazine |
| P769 | significant drug interaction | ... | Q419890 ((±)-flurbiprofen) | (±)-flurbiprofen |
| P769 | significant drug interaction | ... | Q409672 ((RS)-citalopram) | (RS)-citalopram |
| P769 | significant drug interaction | ... | Q410237 (clopidogrel) | clopidogrel |
| P769 | significant drug interaction | ... | Q420262 (rivaroxaban) | rivaroxaban |
| P769 | significant drug interaction | ... | Q420542 (ticagrelor) | ticagrelor |
| P769 | significant drug interaction | ... | Q420685 (rasagiline) | rasagiline |
| P769 | significant drug interaction | ... | Q420885 (tranylcypromine) | tranylcypromine |
| P769 | significant drug interaction | ... | Q421934 (moclobemide) | moclobemide |
| P769 | significant drug interaction | ... | Q422244 (fluoxetine) | fluoxetine |
| P769 | significant drug interaction | ... | Q963093 (sulindac) | sulindac |
| P769 | significant drug interaction | ... | Q1215575 (naproxen) | naproxen |
| P769 | significant drug interaction | ... | Q1640947 (phenindione) | phenindione |
| P769 | significant drug interaction | ... | Q834280 (bupropion) | bupropion |
| P769 | significant drug interaction | ... | Q411377 (linezolid) | linezolid |
| P769 | significant drug interaction | ... | Q411932 ((S)-duloxetine) | (S)-duloxetine |
| P769 | significant drug interaction | ... | Q412050 (prostacyclin) | prostacyclin |
| P769 | significant drug interaction | ... | Q412443 (risperidone) | risperidone |
| P769 | significant drug interaction | ... | Q414028 (meloxicam) | meloxicam |
| P769 | significant drug interaction | ... | Q1747559 (phenelzine) | phenelzine |
| P769 | significant drug interaction | ... | Q2295855 (eptifibatide) | eptifibatide |
| P769 | significant drug interaction | ... | Q2465218 ((RS)-etodolac) | (RS)-etodolac |
| P769 | significant drug interaction | ... | Q423498 (trimipramine) | trimipramine |
| P769 | significant drug interaction | ... | Q425207 (nabumetone) | nabumetone |
| P769 | significant drug interaction | ... | Q481757 (aceclofenac) | aceclofenac |
| P769 | significant drug interaction | ... | Q414462 (apixaban) | apixaban |
| P769 | significant drug interaction | ... | Q414463 (tapentadol) | tapentadol |
| P769 | significant drug interaction | ... | Q415366 (tirofiban) | tirofiban |
| P769 | significant drug interaction | ... | Q898407 (venlafaxine) | venlafaxine |
| P769 | significant drug interaction | ... | Q2555245 ((RS)-fenoprofen) | (RS)-fenoprofen |
| P769 | significant drug interaction | ... | Q3563148 (vortioxetine) | vortioxetine |
| P769 | significant drug interaction | ... | Q3655338 (cangrelor) | cangrelor |
| P769 | significant drug interaction | ... | Q71704041 ((E/Z)-doxepin) | (E/Z)-doxepin |
| P769 | significant drug interaction | ... | Q113368879 (rac-warfarin) | rac-warfarin |
| P769 | significant drug interaction | ... | Q20817139 (iloprost) | iloprost |
| P769 | significant drug interaction | ... | Q47495783 ((−)-selegiline) | (−)-selegiline |
| P9989 | stylized name | String | PARoxetine | ??? |
| P279 | subclass of | ... | Q193430 (heterocyclic compound) | heterocyclic compound |
| P2868 | subject has role | ... | Q334477 (selective serotonin reuptake inhibitor) | selective serotonin reuptake inhibitor |
| P2868 | subject has role | ... | Q50430246 (second-generation antidepressive agents) | second-generation antidepressive agents |
| P2868 | subject has role | ... | Q50430508 (cytochrome P-450 CYP2D6 inhibitors) | cytochrome P-450 CYP2D6 inhibitors |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | paroxetine | ??? |
Why not click here or view trends?
log id: 1823009